The Precision Peptide Company Inc. (CSE:BPC)
Canada · Delayed Price · Currency is CAD | Market Cap | 16.13M +10.8% |
| Revenue (ttm) | 167.35K +2,292.0% |
| Net Income | -7.12M |
| EPS | -0.17 |
| Shares Out | 55.64M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 39,209 |
| Open | 0.3200 |
| Previous Close | 0.3200 |
| Day's Range | 0.2800 - 0.3200 |
| 52-Week Range | 0.1750 - 0.5800 |
| Beta | 0.21 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Mar 3, 2027 |
About CSE:BPC
The Precision Peptide Company Inc. manufactures and distributes plant-based patties and other food products in Canada. The company offers old fashioned ghee; energy gel; and plant-based patty; energy gel products, and munchie mix, as well as custom co-packing, private labelling, product development, and label, design, and regulatory services. It also provides peptide therapies for stress management, gut health, longevity, hair health, skin repair, and sleep health. It distributes its products through its websites, retail outlets, and wholesale ... [Read more]
Financial Performance
In fiscal year 2025, CSE:BPC's revenue was 49,720, an increase of 307.47% compared to the previous year's 12,202. Losses were -4.53 million, 339.0% more than in 2024.
Financial StatementsNews
The Precision Peptide Company Quadruples U.S. Telehealth Formulary to 16 Prescription Therapies Across Seven Therapy Areas
Highlights Prescription formulary grows from 4 to 16 therapies in under 4 months since the Company's nationwide telehealth launch Seven therapy areas now covered: weight management, performance and gr...
The Precision Peptide Company Highlights 30 Years of Peptide Science Behind Its Product Platform
Highlights Chief Scientific Officer Justin Kirkland brings three decades of hands-on peptide synthesis, analytical chemistry and formulation experience to the Company's product platform The Company's ...
The Precision Peptide Company Locks In Exclusive Manufacturing Rights Across Its Needle-Free Line
Four U.S.-made transdermal peptide patches, one manufacturer, one brand: BPC-157 on sale, 20,000 TA1 units in production, Tirzepatide and GLP3 in development Highlights Exclusive manufacturing rights ...
The Precision Peptide Company Begins Development of GLP3 Patch, Its Fourth Needle-Free Peptide
Needle-free line grows to four U.S.-made patches in a peptide market projected to reach US$87.21 billion by 2035 1 Highlights GLP3 transdermal patch enters development in the United States, the fourth...
The Precision Peptide Company Advances Needle-Free GLP-1 Tirzepatide Patch into Formal U.S. Testing
Milestone advances the Company's transdermal peptide patch expanding the Company's growing portfolio across oral, topical and needle-free wellness formats Highlights Formal U.S. testing now underway f...
RETRANSMISSION: The Precision Peptide Company Orders 20,000 Thymosin Alpha-1 Patches for Commercial Launch
Initial U.S. production run moves the Company's second transdermal peptide product from successful testing toward direct-to-consumer and wholesale availability Highlights Order placed for 20,000 units...
The Precision Peptide Company Orders 20,000 Thymosin Alpha-1 Patches for Commercial Launch
Initial U.S. production run moves the Company's second transdermal peptide product from successful testing toward direct-to-consumer and wholesale availability Highlights Order placed for 20,000 units...
The Precision Peptide Company Expands U.S. Wholesale Program, Opening Distribution of Its Needle-Free Range to Clinics, Med Spas, Gyms and Retailers
A second revenue engine for the Company's U.S.-made, needle-free products, built to put them on the shelves where its customers already train, recover and shop Highlights U.S. wholesale channel now op...
The Precision Peptide Company Announces Grants of RSUs and Stock Options
Vancouver, British Columbia--(Newsfile Corp. - September 4, 2026) - The Precision Peptide Company Inc. (CSE: BPC) (OTCQB: PNGAF) (the "Company") announces that on July 31, 2026, it has authorized the ...
The Precision Peptide Company to Showcase Its Needle-Free Recovery Patch and Supplement Range at FitExpo Anaheim
Highlights The Company's supplement range, led by The Recovery Patch, will be available for purchase on site at FitExpo Anaheim, August 29 and 30, 2026 A 15% event discount will be available to attend...
The Precision Peptide Company Completes Migration of Amino Innovations Online Store and Customer Base to Company Website
Vancouver, British Columbia--(Newsfile Corp. - August 7, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advance...
The Precision Peptide Company Targets Launch of the Peptide Pen, Expanding Its U.S.-Made Product Platform
Highlights The Company introduces expected launch of the Peptide Pen, its second commercial product, marking a significant expansion beyond transdermal patches into precision injection delivery Design...
The Precision Peptide Company Opens Nationwide Retail Sales Days After FDA Panel Backs Six of Seven Peptides Under Review
Highlights Seven products are now in stock and available to purchase at precisionpeptidecompany.com: BPC, KPV, Ageless, Chill, Blue, Hair and The Recovery Patch The Recovery Patch is the Company's fir...
The Precision Peptide Company Advances First-to-Market Thymosin Alpha-1 Patch for Immune Support
Highlights Q3/Q4 2026 is the targeted completion period for testing of The Precision Peptide Company's Thymosin Alpha-1 transdermal patch 2025 research continues to evaluate Thymosin Alpha-1 for immun...
The Precision Peptide Company Applauds FDA Advisory Committee Vote on Expanded Pathway for BPC-157 and KPV
On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8-6 (one abstention) to recommend BPC-157 for inclusion on the Section 503A Bulks List. BPC-157 was the first of seven peptide...
The Precision Peptide Company Activates Nationwide Direct-to-Consumer Peptide Sales with Retail Telehealth Website Launch
Highlights The Precision Peptide Company's newly launched direct-to-consumer and telehealth platform is now available in all 50 states of the United States. 100% U.S.-compounded peptide products are s...
The Precision Peptide Company Inc. Announces Closing of LIFE Offering of Common Shares
Vancouver, British Columbia--(Newsfile Corp. - July 15, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), is pleased to announce that further to its news releas...
The Precision Peptide Company Inc. Receives 20,000-Unit Production Run of BPC-157 Transdermal Patches
Highlights Received full production run of approximately 20,000 BPC-157 transdermal patches, the Company's lead product candidate Patches are manufactured and independently tested in the United States...
The Precision Peptide Company Appoints Certified Peptide Therapist and Integrative Health Coach Diane Stafrace to Advisory Board
Key Highlights:
The Precision Peptide Company's Needle-Free Recovery Patch Featured in Men's Health Magazine
Vancouver, British Columbia--(Newsfile Corp. - June 30, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced...
The Precision Peptide Company Achieves LegitScript Healthcare Merchant Certification
Vancouver, British Columbia--(Newsfile Corp. - June 23, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced...
The Precision Peptide Company Announces Release of The Human Upgrade with Dave Asprey Episode Featuring Chief Scientific Officer Justin Kirkland
Vancouver, British Columbia--(Newsfile Corp. - June 16, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced...
The Precision Peptide Company Inc. Announces up to $2 Million LIFE Offering of Common Shares
Vancouver, British Columbia--(Newsfile Corp. - June 11, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC") is pleased to announce that it intends to undertake a n...
The Precision Peptide Company Establishes Compliant U.S. Peptide Access with Telehealth and Prescription Infrastructure Partnership
Highlights Signed an agreement with a U.S.-based prescription telehealth and infrastructure partner to support compliant prescribing, fulfillment, and delivery of the Company's peptide products Builds...
The Precision Peptide Company Inc. Announces Extension of Investor Relations Agreement with Emerging Markets Consulting, LLC
Vancouver, British Columbia--(Newsfile Corp. - June 5, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), is pleased to announce that, further to its news releas...